Back to Dashboard










LABORATORIOS FARMACEUTICOS ROVI (ROVI.MC)
Real-time intraday values
Market Overview
From:
To:
ROVI.MC Intraday
No data available
SymbolROVI.MC
IPO DateDec 5, 2007
CEOMr. Juan Lopez-Belmonte Encina
Full Time Employees2.5k
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountrySpain
ExchangeMCE
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.51% | +0.30 US$ |
| 5 Days | +2.50% | +1.45 US$ |
| 1 Month | +1.62% | +0.95 US$ |
| 6 Months | -18.42% | -13.45 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ROVI.MC...
Key Statistics
Market Cap
3.05B
P/E Ratio
16.45
Div Yield
1.61%
52W High
$86.70
52W Low
$51.65
Analyst Consensus
ConsensusBuy
Bullish444.4%
Neutral555.6%
Bearish00.0%
52W Analyst Price Targets
Min Target
$64.20
$64.20
Max Target
$83.00
$83.00
Current$59.55
Avg Target$74.36
Community Thoughts
Share your analysis and sentiment on ROVI.MC
Join the community to share your analysis
Latest News for ROVI.MC
Son at the double as MLS All-Stars beat Liga MX 4-3
AFP•Jul 30, 2026, 03:19 AM
Is Spotify Technology (SPOT) Fully Valued Going Into Earnings?
Simply Wall St.•Jul 30, 2026, 03:17 AM
Did AI Momentum and France’s Exit Just Shift Palantir Technologies' (PLTR) Investment Narrative?
Simply Wall St.•Jul 30, 2026, 03:16 AM
AutoNation (AN) Jumps On Strong Returns, Is It Still Undervalued?
Simply Wall St.•Jul 30, 2026, 03:16 AM
Is Yum! Brands (YUM) A Bargain As Leadership Changes Raise Fresh Valuation Questions?
Simply Wall St.•Jul 30, 2026, 03:16 AM
Alphabet (GOOGL) Disbands AlphaFold Team As DeepMind Pushes Gemini Further
Simply Wall St.•Jul 30, 2026, 03:16 AM
Is Astera Labs (ALAB) Fairly Valued As Revenue Growth Hits 115%?
Simply Wall St.•Jul 30, 2026, 03:15 AM
Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?
Simply Wall St.•Jul 30, 2026, 03:15 AM
SolarEdge (SEDG) Stock Looks Undervalued Following Its 87% Five Year Slump
Simply Wall St.•Jul 30, 2026, 03:15 AM